Cn. Sternberg et al., Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder, ANN ONCOL, 10(11), 1999, pp. 1301-1305
Background: The possibility of bladder preservation as well as the utility
of neo-adjuvant chemotherapy for invasive bladder cancer are controversial
issues. The purpose of this study was the evaluation of neo-adjuvant M-VAC
chemotherapy and bladder preservation in patients with locally advanced tra
nsitional cell carcinoma of the bladder.
Patients and methods: Eighty-seven consecutive evaluable patients with T-2-
T(4)aN(x)M(0) TCC of the bladder were treated with three cycles of neo-adju
vant M-VAC chemotherapy. After three cycles of M-VAC, 42 patients had TURB
alone, 13 patients underwent partial cystectomy, and 32 patients were to un
dergo radical cystectomy.
Results: Forty (51%) patients were T-0 at the TURB following M-VAC. Thirty
(71%) patients who had chemotherapy and TURB alone are alive; at a median f
ollow-up of 54+ months (8+-109+). Twenty-four (57%) have maintained an inta
ct bladder. Of 13 responding patients with monofocal lesions who underwent
partial cystectomy, 8 patients (62%) are alive with a functioning bladder,
at a median follow-up of 80+ months (16-107+ months). At a follow-up of 32
months (7-121+ months), 20 (63%) patients in the radical cystectomy group a
re alive. In patients who had downstaging to T-0 or superficial disease, me
dian follow-up is 55 months (10-121+ months) and five-year survival is 71%.
Patients who failed to respond (T-2 or greater after chemotherapy), at a m
edian follow-up of 24 months (7-103+ months), had five-year survival of onl
y 29%.
Conclusions: Bladder sparing in selected patients on the basis of response
to neo-adjuvant chemotherapy is a feasible approach which must be confirmed
in prospective randomized trials.